Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Jung-Yeon Lim"'
Publikováno v:
Korean Journal of Clinical Laboratory Science, Vol 56, Iss 3, Pp 198-206 (2024)
EZH2 is a methyltransferase that is a critical target for lymphoma treatment. However, it is not yet widely used in clinical settings. PROteolysis TArgeting Chimeras (PROTACs) represent a novel therapeutic strategy aimed at eliminating proteins that
Externí odkaz:
https://doaj.org/article/895f40d17ec04b28897d1c8e64b227bb
Publikováno v:
Korean Journal of Clinical Laboratory Science, Vol 55, Iss 4, Pp 298-305 (2023)
Burkitt’s lymphoma is a distinct subtype of non-Hodgkin’s lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addre
Externí odkaz:
https://doaj.org/article/c854012f524c4aaeb779051b7335347b
Autor:
Yurim Jeong, Se Been Kim, Chae-Eun Yang, Min Seo Yu, Wan-Su Choi, Youngwoo Jeon, Jung-Yeon Lim
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Enhancer of zeste homolog 2 (EZH2) and Bruton’s tyrosine kinase (BTK) are both key factors involved in the development and progression of hematological malignancies. Clinical studies have demonstrated the potential of various EZH2 inhibitors, which
Externí odkaz:
https://doaj.org/article/9b203ac2db194302a5f5d02fc7901d81
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionB-cell-activating factor (BAFF) is associated with donor-specific antibodies and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the effects of BAFF on T-cell physiol
Externí odkaz:
https://doaj.org/article/1a0041b127194f09943caeb9cb91cd4e
Autor:
Nayoun Kim, Hyunji Lee, Junghoon Shin, Young-Sun Nam, Keon-Il Im, Jung-Yeon Lim, Eun-Sol Lee, Young-Nam Kang, Se-Ho Park, Seok-Goo Cho
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126318 (2015)
Establishing mixed chimerism is a promising approach for inducing donor-specific transplant tolerance. The establishment and maintenance of mixed chimerism may enable long-term engraftment of organ transplants while minimizing the use of immunosuppre
Externí odkaz:
https://doaj.org/article/2963a04dd0c7472486d7524fc1f867db
Autor:
Eun-Sol Lee, Jung-Yeon Lim, Keon-Il Im, Nayoun Kim, Young-Sun Nam, Young-Woo Jeon, Seok-Goo Cho
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138846 (2015)
Therapeutic effects of combined cell therapy with mesenchymal stem cells (MSCs) and regulatory T cells (Treg cells) have recently been studied in acute graft-versus-host-disease (aGVHD) models. However, the underlying, seemingly synergistic mechanism
Externí odkaz:
https://doaj.org/article/466dad12a985470da93515dca904def7
Autor:
Jung-Yeon Lim, Min-Jung Park, Keon-Il Im, Nayoun Kim, Eun-Joo Jeon, Eun-Jung Kim, Mi-La Cho, Seok-Goo Cho M.D., Ph.D
Publikováno v:
Cell Transplantation, Vol 23 (2014)
Mesenchymal stem cells (MSCs) have been considered to be an ideal cellular source for graft-versus-host disease (GVHD) treatment due to their unique properties, including tissue repair and major histocompatibility complex (MHC)-unmatched immunosuppre
Externí odkaz:
https://doaj.org/article/58d282fbb192413a99ccaf7cb3ca1c2c
Autor:
Jung Ho Lee, Eun-Joo Jeon, Nayoun Kim, Young-Sun Nam, Keon-Il Im, Jung-Yeon Lim, Eun-Jung Kim, Mi-La Cho, Ki Taik Han, Seok-Goo Cho
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70968 (2013)
Mesenchymal stromal cells (MSCs) are seen as an ideal source of cells to induce graft acceptance; however, some reports have shown that MSCs can be immunogenic rather than immunosuppressive. We speculate that the immunomodulatory effects of regulator
Externí odkaz:
https://doaj.org/article/181121d264284164b23f3122058a11e5
PDF file - 1.8MB, Upregulation of DR5 after treatment with MK886 in glioma cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5e6e5dc17c601121932ccb3c23b41a
https://doi.org/10.1158/0008-5472.22391565
https://doi.org/10.1158/0008-5472.22391565
